Non-Metastatic Uterine Carcinosarcoma: A Tailored Approach or One Size Fits All?
Open Access
Abstract
Purpose: Uterine carcinosarcomas are highly aggressive tumors of the endometrium and are associated with a poor prognosis. The optimal adjuvant treatment for both early and advanced-stage patients remains unclear. Methods: Cases of uterine carcinosarcoma were identified in our institution’s pathology database between 2000 and 2022. Kaplan–Meier estimates were calculated for the local and distant recurrence-free, disease-free and overall survival; hazard ratios were calculated using Cox proportional hazards modelling for independent prognostic factors including the stage and treatment. Results: A total of 48 patients were identified as having uterine carcinosarcoma, of whom 70.8% were surgically staged. In total, 43 patients had pelvic-confined disease, while five had positive omental or peritoneal biopsies at surgery. There were 10 pelvic (20.8%) and 19 (39.6%) distant recurrences. None of the patients with stage IA disease who received chemotherapy and brachytherapy experienced disease recurrence. The local recurrence-free survival was 54.95%, the distant recurrence-free survival was 44.7%, and the overall survival was 59.6% at 5 years. Local recurrence-free survival and overall survival were inversely associated with advanced-stage OR 1.23 (p = 0.005) and OR 1.28 (p = 0.017), respectively, and no chemotherapy was associated with OR 1.96 (p = 0.06) and OR 2.08 (p = 0.056), respectively. Conclusion: The local and distant recurrence rates were high for advanced=stage patients even when treated with aggressive adjuvant therapy regimens. Chemotherapy may improve recurrence and survival. Early-stage patients may perform well with vaginal vault brachytherapy and chemotherapy. Further prospective comparisons are required between sequential, sandwich, and concurrent approaches to chemotherapy and radiotherapy, to optimize outcomes in this high-risk population.Keywords
This publication has 29 references indexed in Scilit:
- Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcomaGynecologic Oncology Reports, 2022
- Prognostic value of the TCGA molecular classification in uterine carcinosarcomaInternational Journal of Gynecology & Obstetrics, 2021
- Uterine carcinosarcoma: An overviewCritical Reviews in Oncology/Hematology, 2021
- Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: A retrospective cohort studyInternational Journal of Surgery, 2015
- Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcomaCochrane Database of Systematic Reviews, 2013
- Carcinosarcoma of the Uterus—A Single Institution Retrospective Analysis of the Management and Outcome and a Brief Review of LiteratureIndian Journal of Surgical Oncology, 2013
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – Results from two randomised studiesEuropean Journal of Cancer, 2010
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus☆Gynecologic Oncology, 2007
- A Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 2000